Faden Lab

Thank you to our outstanding sponsors making this summit possible: @NateraOncology, @Naveris_inc, @DropletBiosci, @NeoGenomics, @GuardantHealth, @illumina , @HaystackMRD and Adela @MGBResearchNews

📅 July 17, 2026 | 8:30 AM–5:00 PM 📍Broad Institute, 415 Main Street, Cambridge, MA ✅ FREE registration for all (including trainees) ⚠️ 120+ already registered—limited space remaining Register and view the outstanding speaker lineup here: eventleaf.com/e/HeadandNeckC…

🧬 Two months until the inaugural Head and Neck Cancer Liquid Biopsy Summit! July 17, 2026 at @broadinstitute We're bringing together the brightest minds in head and neck cancer liquid biopsy from academia and industry for an immersive day of science and collaboration

What a great series of meeting @AACR and @PacBio . Inspiring science with #liquidbiopsy reshaping all aspects of care. Congrats to our Qin Wang for great presentations. And so cool for our @CCR_AACR paper to be featured as top cancer early detection paper of the year!

The Faden Lab is hiring a Clinical Research Coordinator. Seeking a highly motivated individual to join our dynamic team to support both clinical and laboratory research efforts! View the posting and apply here: linkedin.com/jobs/view/4400…

We look forward to the event, and are proud to be a sponsor!

Looking forward to this summit @broadinstitute - great speaker lineup!

Grateful to our sponsors — @NateraOncology , @Naveris_inc @NeoGenomics @DropletBiosci and Adela @MGBResearchNews

At a time of rapid progress in liquid biopsy, the summit will offer an important opportunity to connect across disciplines, exchange ideas, and discuss the future of cancer detection, monitoring, and clinical care. G

Thrilled to host the inaugural Head and Neck Cancer Liquid Biopsy Summit July 17th, 2026, @broadinstitute in Cambridge MA See the outstanding speaker lineup on the meeting website: eventleaf.com/e/HeadandNeckC… Registration is free and open to all Additional details 👇👇👇

And last but not least, I was truly surprised (and touched) by the cake and champagne celebrating my recent promotion to Associate Professor at Harvard Medical School. It’s an honor to work with, teach, and learn from such remarkable people. @MGBResearchNews @MassGenBrigham

I’m also deeply thankful for an outstanding lab and collaborators here in Boston—who led a terrific journal club last night on emerging ctDNA trials, co-hosted with Viktor Adalsteinsson and his team @broadinstitute.

Feeling especially grateful today for the opportunities that have shaped my early career. Training at @UCSF_OHNS was an incredible experience and gave me the foundation to grow as a surgeon-scientist.

Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical cancers caused by HPV, there is no screening test for HPV-associated head and neck cancers. This means that patients are usually diagnosed after a tumor has grown to billions of cells in size, causing symptoms and spreading to lymph nodes. Screening methods that can detect these cancers much earlier could mean treatment interventions for patients sooner. In a new study, Mass General Brigham researchers show that a novel liquid biopsy tool they developed, called HPV-DeepSeek, can identify HPV-associated head and neck cancer up to 10 years before symptoms appear. By catching cancers earlier with this novel test, patients may experience higher treatment success and require a less intense regimen, according to the authors. spklr.io/6014DwOLC